



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/996,768 12/23/97 WENDEL A P61750USQ

HM22/0725
JACOBSON PRICE HOLMAN & STERN
JENIFER BUILDING
400 SEVENTH STREET NW
WASHINGTON DC 20004

EXAMINER

HINES, J

ART UNIT

PAPER NUMBER

1645

20

DATE MAILED:

07/25/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
08/996,768

Applicant(s)

Wendel et al.

Examiner

Ja-Na Hines

Group Art Unit

1641

☒ Responsive to communication(s) filed on May 4, 2000

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

☒ Claim(s) 19-25 and 27-29 is/are pending in the application

Of the above, claim(s) _____ is/are withdrawn from consideration

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 19-25 and 27-29 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☒ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

Art Unit: 1641

DETAILED ACTION

1. Claims 19-25 and 27-29 are pending in this Office Action.

Specification

2. Applicant is advised on how to arrange the content of the specification.
 - (a) Title of the Invention: See 37 CFR 1.72(a). The title of the invention should be placed at the top of the first page of the specification. It should be brief but technically accurate and descriptive, preferably from two to seven words.
 - (b) Cross-References to Related Applications: See 37 CFR 1.78 and MEP. § 201.11.
 - © Statement Regarding Federally Sponsored Research and Development: See MEP. § 310.
 - (d) Reference to a "Microfiche Appendix": See 37CFR 1.96© and MEP. § 608.05. The total number of microfiche and the total number frames should be specified.
 - (e) Background of the Invention: The specification should set forth the Background of the Invention in two parts:
 - (1) Field of the Invention: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."
 - (2) Description of the Related Art: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."
 - (f) Brief Summary of the Invention: A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of

Art Unit: 1641

the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.

- (g) Brief Description of the Several Views of the Drawing(s): A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74.
- (h) Detailed Description of the Invention: A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. This item may also be titled "Best Mode for Carrying Out the Invention." Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter.
- (i) Claim or Claims: See 37 CFR 1.75 and MEP. § 608.01(m). The claim or claims must commence on separate sheet. (37 CFR 1.52(b)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps.
- (j) Abstract of the Disclosure: A brief narrative of the disclosure as a whole in a single paragraph of 250 words or less on a separate sheet following the claims.
- (k) Drawings: See 37 CFR 1.81, 1.83-1.85, and MEP. § 608.02.
- (l) Sequence Listing: See 37 CFR 1.821-1.825.

Drawings

3. Applicant is required to submit a proposed drawing correction in reply to this Office action. However, formal correction of the noted defect can be deferred until the application is allowed by the examiner.

Art Unit: 1641

Response to Arguments

4. Applicant's arguments filed May 4, 2000 have been fully considered but they are not persuasive.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 19-29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is maintained. Applicants argue that the preamble and final steps recited in the claims are sufficient to make the claim complete. However, the claims are incomplete. The claims state a reaction of blood will be determined, however the final step recites a detecting and/or measuring step. The claims correlation between the related immunofunctional, toxic and/or modulatory reaction to the exposure to test materials. The rejection is maintained.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 19-25 and 27-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wendel et al. (EPA 741,294, DE Appl. 19, 516,247), in view of Boyse et al., (US Patent 5,004,681) is maintained. In response to applicant's argument that there is no suggestion to combine the references, because Boyse et al., (5,004,681), can only be used in therapeutic methods and products, however Boyse et al., teaches

Art Unit: 1641

inspection and testing of the blood can test for the presence of bacterial cultures or diagnostic screening for pathogenic microorganisms. The examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, it would have been obvious to have used the frozen blood samples and cryopreservation of blood as taught by Boyse et al., (5,004,681) in the method of Wendel et al., because frozen blood does not lose its ability to function and cryopreservation can be stored until use and this would provide an advantage in the method of Wendel et al.

7. Claims 19-25 and 27-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wendel et al. (EPA 741,294, DE Appl. 19, 516,247), in view of Dinarello (US Patent 4,434,237) and in further view of Boyse et al., (US Patent 5,192,553) is maintained. Wendel et al., has been discussed above.

In response to applicant's arguments against the references individually, in that Dinarello does not teach the use of whole blood and that Boyse et al., (5,192,553) teaches diagnostic methods and products, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. Wendel et al. (EPA 741,294, DE Appl. 19, 516,247), in view of Dinarello (US Patent 4,434,237) and in further view of Boyse et al., (US Patent 5,192,553) teaches a method of determining the reaction of whole cryopreserved blood wherein the reaction of the blood is measured by particular methods.

Art Unit: 1641

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art.. In this case, it would have been obvious to have used the frozen and cryopreservation techniques of blood as taught by Boyse et al., (US Patent 5,192,553), with the whole blood samples of Wendel et al., and the method of determining the reaction of blood as taught by Dinarello because frozen blood is protected against cellular injury and can be stored and this would provide an advantage in the method of Wendel et al., and Dinarello.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1641

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ja-Na Hines whose telephone number is (703) 305-0487. The examiner can normally be reached on Monday through Thursday from 6:30am to 4:00pm. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Ja-Na Hines *JH*

July 20, 2000

JG 7/24/00
JENNIFER GRASCH
PATENT EXAMINER